KLF15 in vascular disease

KLF15 在血管疾病中的作用

基本信息

  • 批准号:
    8484868
  • 负责人:
  • 金额:
    $ 47.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2016-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The aortic wall is a tightly regulated structure that performs essential functions in a unique hemodynamic environment. Aortic wall homeostasis involves interactions between major structural components and its predominant cellular constituent - the vascular smooth muscle cell. Perturbation of these homeostatic mechanisms secondary to genetic and/or environmental factors can lead to permanent dilatations termed aorta aneurysms (AA). Insights gleaned from clinical, pathologic, and experimental studies indicate that local inflammation of the aorta, fragmentation of the extracellular matrix, and loss f smooth muscle cells are central features of AA. These lesions may occur in both the thoracic and abdominal regions of the aortic tree and can deteriorate to vascular dissection and/or rupture that constitute a significant source of morbidity and mortality. While the molecular pathways governing AA formation remain poorly understood, accumulating evidence implicates activation of the renin-angiotensin system (RAS) as an important contributor to the pathogenesis of AA disease. However, current pharmacotherapies targeting this pathway and others have demonstrated only modest effects suggesting that greater insights into the pathobiology of this disease entity are required to develop effective therapies. Recently published work from our group coupled with nascent observations provided in this application identify the transcription factor Kruppel-like factor 15 (KLF15) as an essential regulator of AA formation. KLF15 expression was found to be strongly reduced in human AA tissues and in aortas of mice following angiotensin II (Ang II) infusion. Mice deficient in KLF15 develop AA characterized by elastin fragmentation, vascular inflammation/dissection, and SMC apoptosis following Ang II infusion. Mechanistically, our studies reveal that KLF15 deficiency increased the levels and activity of p53, a key regulator of smooth muscle cell inflammation and survival. The importance of p53 is underscored by the observation that compound deficiency of KLF15 and p53 ameliorates AA formation. Collectively, these observations provide cogent evidence implicating a previously unrecognized transcriptional axis - that of KLF15/p53 - as critical to the pathogenesis of AA disease. To better understand the role of KLF15 in aneurysmal biology three robust and interrelated aims are proposed. In aim 1, we will assess the effect of vascular specific manipulation of the KLF15-p53 axis on AA formation. In aim 2, we seek to elucidate the molecular mechanism underlying KLF15-mediated alterations in p53 acetylation and activity in vitro. And finally, in aim 3, we will determine the in vivo role of KLF15-dependent regulation of p53 acetylation/activity in AA formation. Collectively, these studies will provide novel insights regarding a previously unappreciated transcriptional pathway governing aortic aneurysm development. Further, the results of these studies may provide the foundation for novel approaches to the treatment of this highly morbid and mortal disease.
描述(由申请人提供):主动脉壁是一个严格调节的结构,在独特的血流动力学环境中发挥重要功能。主动脉壁内稳态涉及主要结构成分与其主要细胞成分血管平滑肌细胞之间的相互作用。继发于遗传和/或环境因素的这些体内平衡机制的扰动可导致永久性扩张,称为主动脉动脉瘤(AA)。从临床、病理和实验研究中收集到的见解表明,主动脉局部炎症、细胞外基质碎裂和平滑肌细胞丧失是AA的主要特征。这些病变可能发生在主动脉树的胸部和腹部区域,并可能恶化为血管剥离和/或破裂,这是发病率和死亡率的重要来源。虽然控制AA形成的分子途径仍然知之甚少,但越来越多的证据表明,肾素-血管紧张素系统(RAS)的激活是AA病发病机制的重要因素。然而,目前针对这一途径和其他途径的药物治疗仅显示出适度的效果,这表明需要对这种疾病实体的病理生物学有更深入的了解,以开发有效的治疗方法。我们小组最近发表的研究成果以及本应用程序提供的初步观察结果表明,转录因子kruppel样因子15 (KLF15)是AA形成的重要调节因子。在血管紧张素II (Ang II)输注后,KLF15在人AA组织和小鼠主动脉中的表达明显降低。缺乏KLF15的小鼠在输注Ang II后发生以弹性蛋白断裂、血管炎症/夹层和SMC凋亡为特征的AA。在机制上,我们的研究表明,KLF15缺陷增加了p53的水平和活性,p53是平滑肌细胞炎症和存活的关键调节因子。观察到KLF15和p53的复合缺乏可改善AA的形成,从而强调了p53的重要性。总的来说,这些观察结果提供了令人信服的证据,表明以前未被认识到的转录轴- KLF15/p53 -对乳腺癌至关重要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MUKESH Kumar JAIN其他文献

MUKESH Kumar JAIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MUKESH Kumar JAIN', 18)}}的其他基金

CWRU- Cardiovascular Research Training Program
CWRU-心血管研究培训计划
  • 批准号:
    10225361
  • 财政年份:
    2017
  • 资助金额:
    $ 47.42万
  • 项目类别:
KLF control of aging and age-associated cardiovascular disease
KLF 控制衰老和与年龄相关的心血管疾病
  • 批准号:
    10560523
  • 财政年份:
    2017
  • 资助金额:
    $ 47.42万
  • 项目类别:
CWRU- Cardiovascular Research Training Program
CWRU-心血管研究培训计划
  • 批准号:
    9358086
  • 财政年份:
    2017
  • 资助金额:
    $ 47.42万
  • 项目类别:
KLF control of aging and age-associated cardiovascular disease
KLF 控制衰老和与年龄相关的心血管疾病
  • 批准号:
    10335213
  • 财政年份:
    2017
  • 资助金额:
    $ 47.42万
  • 项目类别:
Transcriptional control of endothelium in APS by Kruppel Like factors
Kruppel 样因子对 APS 中内皮细胞的转录控制
  • 批准号:
    8926465
  • 财政年份:
    2014
  • 资助金额:
    $ 47.42万
  • 项目类别:
Transcriptional control of endothelium in APS by Kruppel Like factors
Kruppel 样因子对 APS 中内皮细胞的转录控制
  • 批准号:
    9307969
  • 财政年份:
    2014
  • 资助金额:
    $ 47.42万
  • 项目类别:
Transcriptional control of endothelium in APS by Kruppel Like factors
Kruppel 样因子对 APS 中内皮细胞的转录控制
  • 批准号:
    8838964
  • 财政年份:
    2014
  • 资助金额:
    $ 47.42万
  • 项目类别:
KLF15 in Cardiac Metabolism
KLF15 在心脏代谢中的作用
  • 批准号:
    8636146
  • 财政年份:
    2013
  • 资助金额:
    $ 47.42万
  • 项目类别:
KLF15 in Cardiac Metabolism
KLF15 在心脏代谢中的作用
  • 批准号:
    8786599
  • 财政年份:
    2013
  • 资助金额:
    $ 47.42万
  • 项目类别:
KLF15 in Cardiac Metabolism
KLF15 在心脏代谢中的作用
  • 批准号:
    9190383
  • 财政年份:
    2013
  • 资助金额:
    $ 47.42万
  • 项目类别:

相似海外基金

Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
  • 批准号:
    EP/Y000331/1
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
    Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
  • 批准号:
    10677295
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
  • 批准号:
    10635599
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
  • 批准号:
    10752320
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
  • 批准号:
    478927
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
    Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
  • 批准号:
    10855703
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
  • 批准号:
    10654210
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
  • 批准号:
    10733915
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
  • 批准号:
    10667952
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
  • 批准号:
    10726986
  • 财政年份:
    2023
  • 资助金额:
    $ 47.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了